AnzolinAP, GoularteJF, PintoJV, et al.Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation. Front Psychiatry, 2023; 14:1147298; doi: 10.3389/fpsyt.2023.1147298
2.
BestS, PavelDG, HaustrupN. Long-term efficacy of combination therapy of transcranial magnetic stimulation with ketamine for patients with treatment-resistant depression. CNS Spectr, 2021; 26(2):171–171; doi: 10.1017/S1092852920002783
3.
BestSRD, PavelDG, HaustrupN. Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use. Heliyon, 2019; 5(8):e02187; doi: 10.1016/j.heliyon.2019.e02187
4.
BoylanK, MacQueenG, KirkpatrickR, et al.A systematic review of interventions for treatment resistant major depressive disorder in adolescents. Eur Child and Adolesc Psychiatry, 2020; 29(4):433–443; doi: 10.1007/S00787-019-01341-5
5.
BrentD, EmslieG, ClarkeG, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial [published correction appears in JAMA. 2019 Nov 5;322(17):1718].JAMA, 2008; 322(17)(8):901–913; doi: 10.1001/jama.299.8.901
6.
ChenCC, ZhouN, HuN, et al.Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: A systematic review and meta-analysis. Neuropsychiatr Dis Treat, 2023; 19:587–599; doi: 10.2147/NDT.S401032
7.
CullenKR, AmatyaP, RobackMG, et al.Intravenous ketamine for adolescents with treatment-resistant depression: An Open-Label Study [published correction appears in J Child Adolesc Psychopharmacol. 2019 Feb;29(1):77]. J Child Adolesc Psychopharmacol, 2018; 28(7):437–444; doi: 10.1089/cap.2018.0030
8.
Di LazzaroV, OlivieroA, ProficeP, et al.Ketamine increases human motor cortex excitability to transcranial magnetic stimulation. J Physiol, 2003; 547(Pt 2):485–496; doi: 10.1113/jphysiol.2002.030486
9.
DwyerJB, BeyerC, WilkinsonST, et al.Ketamine as a treatment for adolescent depression: A case report. J Am Acad Child Adolesc Psychiatry, 2017; 56(4):352–354; doi: 10.1016/j.jaac.2017.01.006
10.
DwyerJB, Landeros-WeisenbergerA, JohnsonJA, et al.Efficacy of intravenous ketamine in adolescent treatment-resistant depression: A Randomized Midazolam-Controlled Trial. Am J Psychiatry, 2021; 178(4):352–362; doi: 10.1176/appi.ajp.2020.20010018
11.
DwyerJB, StringarisA, BrentDA, et al.Annual Research Review: Defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry, 2020; 61(3):312–332; doi: 10.1111/jcpp.13202
12.
FedgchinM, TrivediM, DalyEJ, et al.Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol, 2019; 22(10):616–630; doi: 10.1093/ijnp/pyz039
13.
Food and Drug Administration. FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression; Available Only at a Certified Doctor's Office or Clinic | FDA; n.d. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified [Last accessed: April21, 2023].
14.
GabrielFC, SteinAT, MeloDO, et al.Guidelines' recommendations for the treatment-resistant depression: A systematic review of their quality. PLoS One, 2023; 18(2):e0281501; doi: 10.1371/journal.pone.0281501
15.
GaynesBN, RushAJ, TrivediMH, et al.The STAR*D study: Treating depression in the real world. Cleve Clin J Med, 2008; 75(1):57–66; doi: 10.3949/ccjm.75.1.57
16.
GhandourRM, ShermanLJ, VladutiuCJ, et al.Prevalence and treatment of depression, anxiety, and conduct problems in US children. J Pediatr, 2019; 206:256–267.e3; doi: 10.1016/j.jpeds.2018.09.021
17.
KimS, RushBS, RiceTR. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. Eur Child Adolesc Psychiatry, 2021; 30(10):1485–1501; doi: 10.1007/s00787-020-01542-3
18.
LeuchterAF, EspinozaR, SuthanaN, et al.Synergistic effects of ketamine and theta burst stimulation in the treatment of major depressive disorder (MDD). Brain Stimul, 2017; 10(2): 492; doi: 10.1016/j.brs.2017.01.438
19.
LiuP, ZhangSS, LiangY, et al.Efficacy and safety of esketamine combined with antidepressants for treatment-resistant depression: A meta-analysis. Neuropsychiatr Dis Treat, 2022; 18:2855–2865; doi: 10.2147/NDT.S388764
20.
MeshkatS, RosenblatJD, RogerCH, et al.Ketamine use in pediatric depression: A systematic review. Psychiatry Res, 2022; 317:114911; doi: 10.1016/j.psychres.2022.114911
21.
MurroughJW, IosifescuDV, ChangLC, et al.Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry, 2013; 170(10):1134–1142; doi: 10.1176/appi.ajp.2013.13030392
22.
Ochs-RossR, WajsE, DalyEJ, et al.Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: Post-hoc analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. Am J Geriatr Psychiatry, 2022; 30(5):541–556; doi: 10.1016/j.jagp.2021.09.014
23.
VasiliuO. Esketamine for treatment-resistant depression: A review of clinical evidence (Review). Exp Ther Med, 2023; 25(3):111; doi: 10.3892/etm.2023.11810
24.
RoyAV, ThaiM, Klimes-DouganB, et al.Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: Preliminary evidence in adolescents with treatment-resistant depression. J Psychopharmacol, 2021; 35(2):168–177; doi: 10.1177/0269881120928203
25.
SuTP, LiCT, LinWC, et al.A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation. Int J Neuropsychopharmacol, 2023; 26(5):331–339; doi: 10.1093/ijnp/pyad014
26.
WalterHJ, AbrightAR, BuksteinOG, et al.Clinical Practice Guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. J Am Acad Child Adolesc Psychiatry, 2023; 62(5):479–502; doi: 10.1016/j.jaac.2022.10.001
27.
WolfsonPE, AndriesJ, AhlersD, et al.Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses. Front Psychiatry, 2023; 14:1141988; doi: 10.3389/fpsyt.2023.1141988
